BeiGene's late stage trial shows promising numbers; Amgen to study sotorasib dosage after FDA recommendation
Big Chinese pharma player BeiGene $BGNE is showing off some promising numbers from its interim analysis of a late-stage, head-to-head trial pitting their BTK drug Brukinsa (zanubrutinib) against Imbruvica.
Reporting on 415 of 652 patients in the ALPINE study, covering adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, investigators say the BeiGene drug has statistically significant results for non-inferiority on objective response rates.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.